Retatrutide is the molecule that made people who follow obesity drugs sit up. If semaglutide acts on one incretin pathway and tirzepatide on two, retatrutide adds a third — it is a single peptide that agonizes the GIP, GLP-1 and glucagon receptors at once. The Phase 2 weight-loss numbers were the largest yet reported for a pharmacological agent, and topline Phase 3 results have since gone even higher. They are also, importantly, not yet FDA-approved numbers. Here is the precise state of the evidence.
What it is, and why a third receptor matters
Retatrutide (formerly LY3437943) is an investigational once-weekly injectable from Eli Lilly. The GLP-1 and GIP components drive the appetite-suppression and insulin-secretion effects familiar from semaglutide and tirzepatide. The novel piece is glucagon-receptor agonism: glucagon raises energy expenditure and promotes hepatic fat mobilization, so the design intent is to pair reduced calorie intake with increased calorie burn. That is the mechanistic theory. The trial below is what actually happened in people.
The headline: the Phase 2 obesity trial
In a 48-week, double-blind, randomized Phase 2 trial, 338 adults with obesity (and without diabetes) received retatrutide at one of several maintenance doses or placebo. At the highest dose (12 mg), participants lost a mean of about 24.2% of body weight, versus roughly 2% with placebo.[1] At 48 weeks the weight-loss curve had not clearly plateaued at the top doses — participants were, on average, still losing weight when the study window closed. That is the detail driving the excitement: the trajectory suggests the ceiling had not yet been reached.
Those magnitudes exceed what semaglutide (about −15% in STEP 1) and tirzepatide (about −21% in SURMOUNT-1) reported — and how it stacks against the dual agonist is laid out in our retatrutide versus tirzepatide comparison. But the comparison must be read with real caution: this is a Phase 2 trial of a few hundred people over under a year, not a Phase 3 outcomes program. Cross-trial comparisons across different populations, durations and designs are suggestive, not definitive.
The diabetes signal
A parallel 36-week Phase 2 trial tested retatrutide in 281 adults with type 2 diabetes. At the 12 mg dose, HbA1c fell 2.02 percentage points at 24 weeks versus 0.01 with placebo (P < 0.0001), and body weight fell 16.94% at 36 weeks versus 3.00% with placebo — a dose-dependent effect on both.[2] So the metabolic effect is not confined to weight: the glucose data are consistent with the incretin components doing what incretin drugs do. Again, the read-out is a mid-stage proof-of-concept, not a cardiovascular or renal outcomes trial.
The honest caveats
Three things deserve emphasis. First, tolerability: like all incretin agents, gastrointestinal side effects (nausea, vomiting, diarrhea) were common and dose-related, and dose escalation matters. Second, the glucagon question: glucagon agonism can raise heart rate and, in theory, perturb glucose handling; the Phase 2 data were reassuring on net glycemia, but long-term cardiometabolic safety is exactly what later-phase trials exist to establish. Third, and most important, retatrutide is not approved anywhere as of this writing — it is in Phase 3 development. There is no long-term outcomes data, no established maintenance dosing outside trials, and nothing legitimately available outside a clinical study.
The honest bottom line
Retatrutide's Phase 2 weight-loss results were the strongest pharmacological signal reported at the time, and the non-plateauing curve at 48 weeks turned out to be an accurate preview: topline Phase 3 results have since reported even larger weight loss. But precision still matters here. Full peer-reviewed Phase 3 data, a completed safety picture — glucagon component included — and an actual FDA submission are all still pending. Until those arrive, the appropriate posture is well-founded optimism, not a verdict. Retatrutide is also no longer the only unconventional bet in the pipeline: a separate group of candidates is testing selective amylin agonism and, in one case, blocking the GIP receptor rather than activating it — see the next wave of obesity drugs.